42 results about "Thyroxine measurement" patented technology

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

A mufti-organ gene profiling analysis of the results of an administration to a subject of salmon calcitonin or a parathyroid hormone analogue provides biomarkers of calcitonin treatment efficacy and parathyroid hormone or parathyroid hormone analogue treatment efficacy. Among the biomarkers are the expression profiles of the genes for Y-box binding protein, BMPs, FGFs, IGFs, VEGF, &x3B1;-2-HS glycoprotein (AHSG), OSF, nuclear receptors (steroid / thyroid family) and others. The results obtained support the anabolic effect of salmon calcitonin on bone metabolism.

The invention provides methods for simultaneously detecting or simultaneously quantifying any combination of thyroxine (T4), triiodothyronine (T3), 3,3′-diiodo-L-thyronine (3,3′-T2), 3-iodothyronamine (T1AM), and, optionally, reverse T3 (rT3) in a sample obtained from a human. The method involves a simple, sensitive, accurate, and specific isotope dilution tandem mass spectrometry method for the simultaneous quantification of any combination of T4, T3, 3,3′-T2, T1AM, and, optionally, rT3 in a sample obtained from a human, e.g., in human plasma or serum samples. This assay is far more sensitive than previously described assays for thyronamines and allows quantitation of T1AM in human plasma or serum, including from healthy controls.

The present invention discloses a virtual screening method of human transthyretin (hTTR) disturbing chemicals, belonging to the field of methods of screening environmental endocrine disturbing chemicals. According to the virtual screening process, firstly, chemicals are classified based on ten radical groups, then a disturbing effect of each chemical on the hTTR is predicted by using a quantitative structure-active relationship model, so that whether the chemical has a capability of disturbing transport of the thyroxine by the hTTR is determined according to a predicted effect value, and the strength of the disturbing capability is also determined. The process of screening the hTTR disturbing chemicals is simple and reasonable, and the method is accurate and reliable, is easy to be programmed, and can be applied to virtual screening of potential hTTR disturbing chemicals in an application domain and priority setting of potential disturbing chemicals.

The inventive medicinal agent for preventing and treating endocrine system disturbances appears as a powder prepared from ossified reindeer horns and contains 120 IU / g of luteinizing hormone, and 54 IU / g of follicle-stimulating hormone, 2,1 IU / g of prolactin, 203 pg / g of adrenocorticotropic hormone, 2,2 ng of somatotropic hormone, thyroidal hormones including 54 fmol / g of free thyroxin, 8 fmp / g of free triiodothyronine, 4,.5 μU / g of thyreotropic hormone, and 25 pmol / g of cortisol.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the inventionhas the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.